ProQR Therapeutics (PRQR) Income from Continuing Operations (2013 - 2025)
ProQR Therapeutics recorded quarterly Income from Continuing Operations of 10589303.85 in Q4 2025, up 19.73% quarter-over-quarter from 13191617.65 in Q3 2025, and up 1.7% year-over-year from 10412224.79 in Q4 2024.
ProQR Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 10589303.85 for Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 1.7% year-over-year to 10589303.85; the TTM figure through Dec 2025 stood at 49023477.82 (down 48.58% YoY), while the FY2025 annual figure was 49104011.62, down 65.51% from the prior year.
- Income from Continuing Operations came in at 10589303.85 for Q4 2025 at ProQR Therapeutics, up from 13191617.65 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3876795.27 in Q2 2024 to a low of 19987022.04 in Q3 2022.
- A 5-year average of 12634493.69 and a median of 12044732.13 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 329.75% in 2021 and jumped 59.75% in 2023, its largest moves.
- ProQR Therapeutics' Income from Continuing Operations stood at 19822728.64 in 2021, then soared by 35.87% to 12712282.17 in 2022, then surged by 46.95% to 6743991.35 in 2023, then sank by 59.73% to 10772510.23 in 2024, then gained by 1.7% to 10589303.85 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 10589303.85, 13191617.65, and 13865374.22 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | -10.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.59 Mn |
| Sep 30, 2025 | -13.19 Mn |
| Jun 30, 2025 | -13.87 Mn |
| Mar 31, 2025 | -11.38 Mn |
| Dec 31, 2024 | -10.77 Mn |
| Sep 30, 2024 | -9.57 Mn |
| Jun 30, 2024 | -3.88 Mn |
| Mar 31, 2024 | -8.77 Mn |
| Dec 31, 2023 | -6.74 Mn |
| Sep 30, 2023 | -8.05 Mn |
| Jun 30, 2023 | -9.59 Mn |
| Mar 31, 2023 | -10.08 Mn |
| Dec 31, 2022 | -12.71 Mn |
| Sep 30, 2022 | -19.99 Mn |
| Jun 30, 2022 | -16.89 Mn |
| Mar 31, 2022 | -19.13 Mn |
| Dec 31, 2021 | -19.82 Mn |
| Sep 30, 2021 | -17.17 Mn |
| Jun 30, 2021 | -15.90 Mn |
| Mar 31, 2021 | -14.60 Mn |
| Dec 31, 2020 | -13.91 Mn |
| Sep 30, 2020 | -12.69 Mn |
| Jun 30, 2020 | -3.70 Mn |
| Mar 31, 2020 | -18.19 Mn |
| Dec 31, 2019 | -19.29 Mn |
| Sep 30, 2019 | -14.96 Mn |
| Jun 30, 2019 | -13.30 Mn |
| Mar 31, 2019 | -16.75 Mn |
| Dec 31, 2018 | -14.67 Mn |
| Sep 30, 2018 | -6.88 Mn |
| Jun 30, 2018 | -9.15 Mn |
| Mar 31, 2018 | 12.11 Bn |
| Dec 31, 2017 | 12.63 Mn |
| Sep 30, 2017 | 11.34 Bn |
| Jun 30, 2017 | -11.19 Mn |
| Mar 31, 2017 | 10.59 Mn |
| Dec 31, 2016 | -11.07 Mn |
| Sep 30, 2016 | -11.02 Mn |
| Jun 30, 2016 | -12.01 Mn |
| Mar 31, 2016 | -9.72 Mn |
| Dec 31, 2015 | -8.26 Mn |
| Sep 30, 2015 | -6.97 Mn |
| Jun 30, 2015 | -7.13 Mn |
| Mar 31, 2015 | -7.62 Mn |
| Dec 31, 2014 | -6.20 Mn |
| Sep 30, 2014 | -6.42 Mn |
| Mar 31, 2014 | -2.54 Mn |
| Dec 31, 2013 | -2.20 Mn |
| Sep 30, 2013 | -1.17 Mn |